These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 16093981

  • 1. High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study.
    Tiffany NM, Ryan CW, Garzotto M, Wersinger EM, Beer TM.
    J Urol; 2005 Sep; 174(3):888-92. PubMed ID: 16093981
    [Abstract] [Full Text] [Related]

  • 2. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
    Efstathiou E, Bozas G, Kostakopoulos A, Kastritis E, Deliveliotis C, Antoniou N, Skarlos D, Papadimitriou C, Dimopoulos MA, Bamias A.
    Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
    [Abstract] [Full Text] [Related]

  • 3. A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer.
    Lin AM, Rini BI, Derynck MK, Weinberg V, Park M, Ryan CJ, Rosenberg JE, Bubley G, Small EJ.
    Clin Genitourin Cancer; 2007 Jun; 5(5):323-8. PubMed ID: 17645829
    [Abstract] [Full Text] [Related]

  • 4. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
    Oudard S, Banu E, Beuzeboc P, Voog E, Dourthe LM, Hardy-Bessard AC, Linassier C, Scotté F, Banu A, Coscas Y, Guinet F, Poupon MF, Andrieu JM.
    J Clin Oncol; 2005 May 20; 23(15):3343-51. PubMed ID: 15738542
    [Abstract] [Full Text] [Related]

  • 5. Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma.
    Mackler NJ, Pienta KJ, Dunn RL, Cooney KA, Redman BG, Olson KB, Fardig JE, Smith DC.
    Clin Genitourin Cancer; 2007 Jun 20; 5(5):318-22. PubMed ID: 17645828
    [Abstract] [Full Text] [Related]

  • 6. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer.
    Nelius T, Klatte T, Yap R, Kalinski T, Röpke A, Filleur S, Allhoff EP.
    BJU Int; 2006 Sep 20; 98(3):580-5. PubMed ID: 16925757
    [Abstract] [Full Text] [Related]

  • 7. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.
    Oh WK, Halabi S, Kelly WK, Werner C, Godley PA, Vogelzang NJ, Small EJ, Cancer and Leukemia Group B 99813.
    Cancer; 2003 Dec 15; 98(12):2592-8. PubMed ID: 14669278
    [Abstract] [Full Text] [Related]

  • 8. Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer.
    Wilding G, Soulie P, Trump D, Das-Gupta A, Small E.
    Cancer; 2006 May 01; 106(9):1917-24. PubMed ID: 16568471
    [Abstract] [Full Text] [Related]

  • 9. Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: a single-center experience.
    Boehmer A, Anastasiadis AG, Feyerabend S, Nagele U, Kuczyk M, Schilling D, Corvin S, Merseburger AS, Stenzl A.
    Anticancer Res; 2005 May 01; 25(6C):4481-6. PubMed ID: 16334130
    [Abstract] [Full Text] [Related]

  • 10. A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.
    Oh WK, Hagmann E, Manola J, George DJ, Gilligan TD, Jacobson JO, Smith MR, Kaufman DS, Kantoff PW.
    Clin Cancer Res; 2005 Jan 01; 11(1):284-9. PubMed ID: 15671557
    [Abstract] [Full Text] [Related]

  • 11. Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel.
    Petrioli R, Pascucci A, Francini E, Marsili S, Sciandivasci A, De Rubertis G, Barbanti G, Manganelli A, Salvestrini F, Francini G.
    BJU Int; 2007 Oct 01; 100(4):775-9. PubMed ID: 17535276
    [Abstract] [Full Text] [Related]

  • 12. Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate- specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD, Meluch AA, Spigel DR, Yost K, Meng C, Greco FA.
    Clin Genitourin Cancer; 2006 Mar 01; 4(4):287-92. PubMed ID: 16729913
    [Abstract] [Full Text] [Related]

  • 13. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.
    Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Redfern CH, Fehrenbacher L, Saleh MN, Waterhouse DM, Carducci MA, Vicario D, Dreicer R, Higano CS, Ahmann FR, Chi KN, Henner WD, Arroyo A, Clow FW, ASCENT Investigators.
    J Clin Oncol; 2007 Feb 20; 25(6):669-74. PubMed ID: 17308271
    [Abstract] [Full Text] [Related]

  • 14. Phase II study of low-dose docetaxel/estramustine in elderly patients or patients aged 18-74 years with hormone-refractory prostate cancer.
    Chittoor S, Berry W, Loesch D, Logie K, Fleagle J, Mull S, Boehm KA, Zhan F, Asmar L.
    Clin Genitourin Cancer; 2006 Dec 20; 5(3):212-8. PubMed ID: 17239275
    [Abstract] [Full Text] [Related]

  • 15. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
    Fizazi K, Faivre L, Lesaunier F, Delva R, Gravis G, Rolland F, Priou F, Ferrero JM, Houede N, Mourey L, Theodore C, Krakowski I, Berdah JF, Baciuchka M, Laguerre B, Fléchon A, Ravaud A, Cojean-Zelek I, Oudard S, Labourey JL, Chinet-Charrot P, Legouffe E, Lagrange JL, Linassier C, Deplanque G, Beuzeboc P, Davin JL, Martin AL, Habibian M, Laplanche A, Culine S.
    Lancet Oncol; 2015 Jul 20; 16(7):787-94. PubMed ID: 26028518
    [Abstract] [Full Text] [Related]

  • 16. A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004.
    Dawson NA, Halabi S, Ou SS, Biggs DD, Kessinger A, Vogelzang N, Clamon GH, Nanus DM, Kelly WK, Small EJ, Cancer And Leukemia Group B.
    Clin Genitourin Cancer; 2008 Sep 20; 6(2):110-6. PubMed ID: 18824434
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Combination chemotherapy with weekly docetaxel and estramustine for hormone refractory prostate cancer in Japanese patients.
    Takenaka A, Yamada Y, Kurahashi T, Soga H, Miyake H, Fujisawa M.
    Int J Urol; 2008 Jan 20; 15(1):106-9. PubMed ID: 18184188
    [Abstract] [Full Text] [Related]

  • 20. Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer.
    Ferrero JM, Chamorey E, Oudard S, Dides S, Lesbats G, Cavaglione G, Nouyrigat P, Foa C, Kaphan R.
    Cancer; 2006 Aug 15; 107(4):738-45. PubMed ID: 16826591
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.